|
1
|
Lopez-Beltran A, Carrasco JC, Cheng L,
Scarpelli M, Kirkali Z and Montironi R: 2009 update on the
classification of renal epithelial tumors in adults. Int J Urol.
16:432–443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hutson TE and Figlin RA: Renal cell
cancer. Cancer J. 13:282–286. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim SP, Weight CJ, Leibovich BC, Thompson
RH, Costello BA, Cheville JC, Lohse CM and Boorjian SA: Outcomes
and clinicopathologic variables associated with late recurrence
after nephrectomy for localized renal cell carcinoma. Urology.
78:1101–1106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Figlin R, Sternberg C and Wood CG: Novel
agents and approaches for advanced renal cell carcinoma. J Urol.
188:707–715. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eisen T, Sternberg CN, Robert C, Mulders
P, Pyle L, Zbinden S, Izzedine H and Escudier B: Targeted therapies
for renal cell carcinoma: Review of adverse event management
strategies. J Natl Cancer Inst. 104:93–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Je Y, Schutz FA and Choueiri TK: Risk of
bleeding with vascular endothelial growth factor receptor
tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic
review and meta-analysis of clinical trials. Lancet Oncol.
10:967–974. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gunsilius E, Petzer AL and Gastl G:
Vascular endothelial growth factor platelet counts and renal
cancer. Lancet. 353:22471999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu G, Li H, Wang J, Gumireddy K, Li A, Yao
W, Tang K, Xiao W, Hu J, Xiao H, et al: miRNA-34a suppresses cell
proliferation and metastasis by targeting CD44 in human renal
carcinoma cells. J Urol. 192:1229–1237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dey N, Das F, Ghosh-Choudhury N, Mandal
CC, Parekh DJ, Block K, Kasinath BS, Abboud HE and Choudhury GG:
microRNA-21 governs TORC1 activation in renal cancer cell
proliferation and invasion. PLoS One. 7:e373662012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakada C, Matsuura K, Tsukamoto Y,
Tanigawa M, Yoshimoto T, Narimatsu T, Nguyen LT, Hijiya N, Uchida
T, Sato F, et al: Genome-wide microRNA expression profiling in
renal cell carcinoma: Significant down-regulation of miR-141 and
miR-200c. J Pathol. 216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Landgraf P, Rusu M, Sheridan R, Sewer A,
Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M,
et al: A mammalian microRNA expression atlas based on small RNA
library sequencing. Cell. 129:1401–1414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh A, Happel C, Manna SK,
Acquaah-Mensah G, Carrerero J, Kumar S, Nasipuri P, Krausz KW,
Wakabayashi N, Dewi R, et al: Transcription factor NRF2 regulates
miR-1 and miR-206 to drive tumorigenesis. J Clin Invest.
123:2921–2934. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: Dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Liu X, Jin H, Guo X, Xia L, Chen
Z, Bai M, Liu J, Shang X, Wu K, et al: miR-206 inhibits gastric
cancer proliferation in part by repressing cyclinD2. Cancer Lett.
332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keklikoglou I, Hosaka K, Bender C, Bott A,
Koerner C, Mitra D, Will R, Woerner A, Muenstermann E, Wilhelm H,
et al: MicroRNA-206 functions as a pleiotropic modulator of cell
proliferation, invasion and lymphangiogenesis in pancreatic
adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene.
34:4867–4878. 2015. View Article : Google Scholar :
|
|
20
|
Yan D, Dong XE, Chen X, Wang L, Lu C, Wang
J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits
rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chu TF, Rupnick MA, Kerkela R, Dallabrida
SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai
J, et al: Cardiotoxicity associated with tyrosine kinase inhibitor
sunitinib. Lancet. 370:2011–2019. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stahlhut C, Suárez Y, Lu J, Mishima Y and
Giraldez AJ: miR-1 and miR-206 regulate angiogenesis by modulating
VegfA expression in zebrafish. Development. 139:4356–4364. 2012.
View Article : Google Scholar : PubMed/NCBI
|
